Free Trial
TSE:ONC

Oncolytics Biotech (ONC) Stock Price, News & Analysis

Oncolytics Biotech logo
C$1.38 -0.02 (-1.43%)
(As of 02:00 PM ET)

About Oncolytics Biotech Stock (TSE:ONC)

Key Stats

Today's Range
C$1.38
C$1.40
50-Day Range
C$1.18
C$1.91
52-Week Range
C$1.15
C$2.32
Volume
29,402 shs
Average Volume
70,504 shs
Market Capitalization
C$106.07 million
P/E Ratio
N/A
Dividend Yield
0.31%
Price Target
C$3.50
Consensus Rating
Buy

Company Overview

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Oncolytics Biotech Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
28th Percentile Overall Score

ONC MarketRank™: 

Oncolytics Biotech scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Oncolytics Biotech has only been the subject of 1 research reports in the past 90 days.

  • Read more about Oncolytics Biotech's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oncolytics Biotech is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oncolytics Biotech is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oncolytics Biotech has a P/B Ratio of 5.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Oncolytics Biotech's valuation and earnings.
  • Short Interest

    There is no current short interest data available for ONC.
  • Dividend Yield

    Oncolytics Biotech has a dividend yield of 0.31%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Oncolytics Biotech does not have a long track record of dividend growth.

  • Read more about Oncolytics Biotech's dividend.
  • Short Interest

    There is no current short interest data available for ONC.
  • News Sentiment

    Oncolytics Biotech has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 30 news articles for Oncolytics Biotech this week, compared to 1 article on an average week.
  • Search Interest

    4 people have searched for ONC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.82% of the stock of Oncolytics Biotech is held by insiders.

  • Percentage Held by Institutions

    Only 1.75% of the stock of Oncolytics Biotech is held by institutions.

  • Read more about Oncolytics Biotech's insider trading history.
Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

ONC Stock News Headlines

Brokers Offer Predictions for TSE:ONC FY2024 Earnings
FY2024 Earnings Estimate for TSE:ONC Issued By HC Wainwright
2024 Election Year Stocks: Uncover Hidden Gems!
In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.
Cantor Fitzgerald Predicts TSE:ONC FY2024 Earnings
FY2024 EPS Estimates for TSE:ONC Decreased by Raymond James
Oncolytics Biotech (ONCY) Gets a Buy from RBC Capital
See More Headlines

ONC Stock Analysis - Frequently Asked Questions

Oncolytics Biotech's stock was trading at C$1.79 on January 1st, 2024. Since then, ONC shares have decreased by 22.3% and is now trading at C$1.39.
View the best growth stocks for 2024 here
.

Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), Ballard Power Systems (BLDP), (ONCYF) (ONCYF), Resverlogix (RVX), Birchcliff Energy (BIR), Enbridge (ENB) and Barrick Gold (GOLD).

Company Calendar

Today
11/21/2024
Next Earnings (Estimated)
3/06/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
C$3.50
High Stock Price Target
C$3.50
Low Stock Price Target
C$3.50
Potential Upside/Downside
+153.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
C$-28,020,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.33 per share
Book Value
C$0.24 per share

Miscellaneous

Free Float
N/A
Market Cap
C$106.07 million
Optionable
Not Optionable
Beta
1.35
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (TSE:ONC) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners